Published Results

Peer-reviewed publications citing Techulon's drug delivery platform products including Glycofect reagent are beginning to appear following Glycofect's market introduction in 2010.  Results are confirming Glycofect's low toxicity and high efficiency in delivery of nucleic acids to cells of research and therapeutic interest. 

Studies in vivo

“In Vivo Delivery of Nucleic Acids via Glycopolymer Vehicles Affords Therapeutic Infarct Size Reduction in Vivo,” Tranter, Liu, He, Gulick, Ren, Robbins, Jones and Reineke, Molecular Therapy, December 20, 2012.   Publication    Press Release
 

Studies in vitro

"Poly(galactaramidoamine) is an efficient cationic polymeric non-viral vector with low cytotoxicity for transfecting human embryonic kidney (HEK293) and murine macrophage (RAW264.7) cells", Wongrakpanich, Joshi and Salem, Pharmaceutical Development and Tec hnology, January 12, 2012.     Publication     Press Release
 

Background Publications

K. Kizjakina, J. Bryson, G. Grandinetti, T.M. Reineke, "Cationic glycoplomers for the delivery of pDNA to human dermal fibroblasts and rat mesenchymal stem cells", Biomaterials, 33, 1851-1862

T.M. Reineke "PGAAs: " Cationic Glycopolymers for DNA Delivery" J. Polym. Sci. A: Polym. Chem. 2006, 44, 6895-6908.

Y. Liu, T.M. Reineke, "Poly(glycoamidoamine)s for Gene Delivery. Stability of Polyplexes and Efficacy with Cardiomyoblast Cells" Bioconjugate Chem. 2006, 17, 101-108.

Y. Liu, T.M. Reineke, "Degradation of Poly(glycoamidoamine) DNA Delivery Vehicles: Polyamide Hydrolysis at Physiological Conditions Promotes DNA Release." Biomacromolecules, 2010, 11, 316.

Y. Liu, T.M. Reineke, "Hydroxyl Stereochemistry and Amine Number wihin Poly(glycoamidoamine)s Affect Intracellular DNA Delivery." J. Am. Chem. Soc., 2005, 127, 3004